Introduction
Colorectal cancer (CRC) poses a significant problem throughout the world as reflected by its annual worldwide incidence of over one million (1 023 152). 1 It is estimated that approximately 15% (153 473) of these CRC cases are familial and that an additional 10% (102 315) are hereditary. Worldwide, Lynch syndrome, also referred to as hereditary nonpolyposis CRC (HNPCC) is the most common hereditary variant of CRC, accounting for 42% (20 463 ) and probably o5% (51 158) of new cases annually.
2,3
Lynch syndrome is characterized by early age at onset of CRC, excess of synchronous and metachronous CRCs, a predilection to the proximal colon, accelerated carcinogenesis, and an excess risk for extracolonic cancers (including endometrium and, to a lesser extent, ovary, stomach, hepatobiliary tract, small bowel, pancreas, brain, transitional cell carcinoma of the ureter and renal pelvis, and, in the Muir -Torre syndrome variant of the Lynch syndrome, sebaceous tumors. 2, 3 Pathology findings in the Lynch syndrome include tumor-infiltrating lymphocytes, signet ring cells, and a strong mucinous component. 4, 5 Figure 1 shows the pedigree of a Lynch syndrome family (Muir -Torre syndrome variant) displaying an array of extracolonic cancers. During the past decade, advances in molecular genetics have provided new insights into the etiology of a number of hereditary gastrointestinal cancers, enabling greater precision in hereditary cancer syndrome identification. 6 Because of the complexity of hereditary cancer syndromes, the challenge to the clinician is the need to understand the natural history of hereditary cancer syndromes and their molecular genetics, which together can improve diagnosis, surveillance, and management strategies for cancer control. To effectively accomplish this, a detailed family history is needed, together with genetic counseling. 2, 3 First of all, it is important to understand that hereditary disorders of the gastrointestinal tract are not rare. Familial adenomatous polyposis (FAP) accounts for much o1% of the total CRC burden, in comparison to the more prevalent Lynch syndrome (Figure 2 ). Insufficiently detailed collection of family history and/or limited knowledge of syndrome phenotype contribute to nonrecognition of affected patients and families. The presence of a deleterious germline mutation in the patient/family will enable a high level of diagnostic certainty in hereditary CRC syndromes such as FAP with its APC mutation, and the Lynch syndrome with mutations in mismatch repair (MMR) genes (MSH2, MLH1, MSH6, PMS2).
Molecular genetic heterogeneity must be considered when assessing the Lynch syndrome cancer phenotype. While more evidence will be required to substantiate differences in phenotype, current data suggest that MLH1 mutations have a higher expression of CRC than do MSH2 mutations, which have more extracolonic cancers and Muir -Torre features. MSH6 mutations, when compared with those of MLH1 and MSH2, show a lower expression of CRC but an excess of endometrial cancer. The phenotypic consequences of PMS2 mutations appear to be highly variable, often with childhood onset of atypical tumors, but the number of observations is too limited for firm conclusions at this time.
Common mutations
Mutations that are widespread can be either recurrent, that is occurring repeatedly de novo, or ancestral (founder mutations), having occurred once and passed on to numerous progeny. The best-known recurrent mutation causing Lynch syndrome is an A-T transversion in the donor splice site of intron 5 of MSH2 (designation c.942 þ 3A-T). 7, 8 This mutation apparently arises repeatedly because the region is vulnerable to slippage during the DNA replication process, the mutated nucleotide being the first in a microsatellite consisting of 26 adenines. It occurs worldwide 9 and may account for as much as 5 -10% of all Lynch syndrome. 10 The ability of an ancestral mutation to persist and become widespread in a population even though it causes a serious condition such as Lynch syndrome (lethal in the era before surgery) is explained by the fact that reproduction is not significantly affected. Thus, some Lynch syndrome founder mutations have become quite common in typical founder populations. In Finns, a genomic deletion of exon 16 of MLH1 probably dates back 1000 years or more and in parts of Finland accounts for 450% of all Lynch syndrome. 11, 12 Other highly enriched founder mutations have been documented in Ashkenazi Jews (MSH2 1906G-C; accounting for B20% of Lynch syndrome 13 ) and other genetically isolated populations (for review see de la Chapelle 14 ).
Founder mutations usually occur in isolated populations that favor enrichment through bottlenecks and genetic drift. The existence of a founder mutation in the general US population was not expected; but in fact one such mutation was uncovered very recently, 15, 16 namely, a deletion of exons 1 -6 of MSH2. This mutation had remained undiscovered because it was not detectable by standard methods such as sequencing.
This exon 1 -6 deletion in MSH2 was originally detected in nine apparently unrelated multigenerational kindreds with Lynch syndrome, 17 and has subsequently been identified in 13 more families (Lynch, unpublished data, 2005) . The sequence of the breakpoints of this exon 1 -6 deletion and the haplotypes surrounding the mutation were identical in all nine kindreds, 15, 17, 18 suggesting a common origin of the mutation. It was subsequently traced through three of the original nine kindreds by genealogy studies through 11 -12 generations to a putative common founder who migrated from Germany to the US in 1727. 17 Based on our pedigrees and published epidemiology data, we estimate that there are at least 19 000 expected living AFM carriers in the United States. 19 The original nine families with the AFM account for 13% (9/70) of families with Lynch syndrome that had been tested and found to be 'negative' for MMR mutations by conventional mutation screening techniques. The high percentage of this founder mutation among Lynch syndrome cases bears significant implications for cancer control. Testing for recurrent and founder mutations as a first step may considerably facilitate the molecular diagnosis of the disease in the appropriate populations.
Children with homozygous MLH1 mutation The carrier rate for heterozygous mutations in MMR genes in Lynch syndrome remains elusive. However, the marriage of two carriers would lead to the probability that one in four of their offspring would be homozygous for the mutation. Homozygous and compound heterozygous MMR gene mutations in children had formerly been described as predisposing to leukemia, lymphoma, and brain tumors, and cafe´au lait spots in the absence of gastrointestinal carcinomas. However, Gallinger et al 20 have reported the first known instance of children with homozygous MMR gene deficiency manifesting early-onset gastrointestinal cancers in concert with neurofibromatosis type 1 (NF1) features. All three members of one sibship 'yhad a germline homozygous MLH1 missense mutation (exon 18, codon 687, CGGTGG), whereas both parents were heterozygous for this mutation.' It is noted that any progeny from two heterozygous MMR mutation carriers will have a one-in-four chance of being compound heterozygotes or true homozygotes, in which case they would be likely to manifest a stronger predisposition to cancer than would be the case for those who are heterozygotes. It is worth noting that these individuals are extremely rare.
Modifier genes
Interindividual variations in the genome can be unrelated to disease, especially when they occur outside of genes. In contrast, variations in genes, especially in the coding regions, have the potential of causing phenotypic Recently, it was proposed that the well-known polymorphism in codon 72 of the TP53 gene has a profound effect on the age of onset of CRC in Lynch syndrome, 24 and the findings were confirmed by Kruger et al. 25 However, in a third study, 26 no such effect was seen. This illustrates the fact that genetic association studies are, especially whenever the studied effect is relatively subtle, difficult to interpret and often contradictory.
Microsatellite instability (MSI) and immunohistochemistry (IHC) screening
Vasen and Boland 27 note that MSI in CRC was discovered in 1993, 28, 29 (cited by Vasen and Boland) and subsequently it was found that MSI was present in colon cancer tissue from most Lynch syndrome patients 30 -32 (cited by Vasen and Boland). However, the molecular genetic sine qua non for Lynch syndrome diagnosis is a germline mutation in one of the MMR genes. The major MMR genes that harbor causal mutations for Lynch syndrome are MSH2, MLH1, MSH6 and PMS2. Individuals with such mutations have an E70% -85% risk, based on the mutation's penetrance, to develop CRC by the age of 60 years. 33 A subset of MMR germline mutations involving large deletions of entire exons are often unidentifiable using regular testing techniques. However, they can be found through various alternative techniques such as those used to identify the already-mentioned MSH2 exon 1 -6 deletion. 15, 17 From the standpoint of the clinician, it is important to consider the role of MSI and immunohistochemical (IHC) staining, either separately or in combination, as intermediate instruments of screening for the Lynch syndrome. 34 Should all CRC-affected individuals be tested? According to one school of thought, the answer is yes. 10 It would be costly and, therefore, should be tested in larger clinical trials, for example, using IHC as the primary screen, to determine if it leads to considerable saving. Thus, the cost effectiveness could be determined more precisely before any general recommendations would be made. 10, 34 MSI and loss of expression of MLH1 by IHC in tumors of older subjects is more likely to be related to hypermethylation of the MLH1 promoter and thereby will carry a very low positive predictive value for the Lynch syndrome, particularly when present in the absence of a family history targeting the syndrome. An assay for methylation of the MLH1 promoter, is a relatively simple way of determining whether MSI or loss of the MLH1 protein on IHC staining is likely (no methylation) or unlikely (methylation) to signal Lynch syndrome.
In discussing the strategy for using MSI and IHC molecular markers, Vasen and Boland 27 suggest that IHC may aid in the search for mutations to a specific gene, while in those patients who meet the Bethesda guidelines they suggest that the first step might be MSI analysis followed by IHC of all tumors classified as MSI-high (MSI-H) 35 (cited by Vasen and Boland). While recognizing that MSI and IHC have been available for only a very short time, Vasen and Boland also urge that every effort be made to extend the current small-scale use of these molecular diagnostic tools in order to make them available to all clinicians. However, in order for this effort to be successful, clinicians must become familiar with the pros and cons of these tests as well as the Bethesda guidelines (Table 1) . 27 Two major questions arise, first, should Lynch syndrome be searched for more actively than hitherto, and second, what should be the primary screening method? Family history is regrettably often ignored 36 ; moreover, both family history and age are losing their sensitivity to detect Lynch syndrome as family size decreases and the more atypical phenotypes associated with MSH6 and PMS2 mutations are taken into account. and MSI and found an excellent correlation between the two. This argues in favor of the much simpler IHC; however, it is unclear why in this study so few patients had abnormal IHC/MSI (6%) and so few had Lynch syndrome (0.7%). As a conclusion, we take the position that IHC loss of protein expression is the most desirable test to screen for Lynch syndrome. 
Genetic/environmental interaction

Genetic counseling
It is important that genetic counseling take place prior to DNA collection and testing, as well as at the time of disclosure of results, since the presence of a cancer-causing germline mutation may impact heavily on the patient's emotions when dealing with his or her lifetime destiny for cancer. Thus, this precious and potentially lifesaving knowledge will enable disclosure of risk for cancer(s) of specific anatomic sites, their average age of onset, prognostic implications, and possibly even chemotherapy choices 40 -49 (discussed subsequently), in the patient bearing the specific cancer-causing mutation. This knowledge will be limited only by the deleterious mutation's penetrance and the mentioned potential impact of environmental carcinogenic interaction. Counselors must be prepared to discuss patients' psychological concerns and thereby address freely such issues as survivor guilt if the patient is found to be negative for the deleterious mutation, or, if positive, concerns about insurance and employment discrimination. Surveillance and management must be addressed, in the interest of compliance with these potentially life-saving measures, all in context with possible fear, anxiety, and apprehension about his or her long-term cancer destiny.
Family information session (FIS)
Cancer control and sound psychological objectives can be significantly abetted through a FIS. 50 This involves the participation of as many family members as desire to assemble at an educational session, in a geographic area of convenience to the family. The FIS is conducted by a physician, a study coordinator who may be a registered Hereditary nonpolyposis colorectal cancer (HNPCC)-associated tumors include colorectal, endometrial, stomach, ovarian, pancreas, ureter or renal pelvis, biliary tract, and brain (usually glioblastoma as seen in Turcot syndrome) tumors, sebaceous gland adenomas and keratoacanthomas in Muir -Torre syndrome, and carcinoma of the small bowel. b MSI-H ¼ microsatellite instability-high in tumors refers to changes in two or more of the five National Cancer Institute-recommended panels of microsatellite markers. c Presence of tumor-infiltrating lymphocytes, Crohn's disease-like lymphocytic reaction, mucinous/signet-ring differentiation, or medullary growth pattern. d There was no consensus among the Workshop participants on whether to include the age criteria in guideline 3 above; participants voted to keep o60 years of age in the guidelines. nurse, and a genetic counselor. Participants are educated in depth about the natural history of the particular hereditary cancer syndrome in their family, availability of genetic testing, and the surveillance and management options available to them. Blood draws for germline mutation testing, when indicated, will follow genetic counseling on consenting individuals.
These
Confidentiality issues
One of the thorniest issues in genetic counseling pertains to the role of confidentiality and the extent of disclosure of cancer risk information, such as the presence of a cancercausing germline mutation of the APC gene in FAP, or of an MMR gene in the Lynch syndrome, to an affected individual's close at-risk relatives. This disclosure may be particularly problematic when that gene carrier is strongly opposed to disseminating this information to at-risk relatives. Thus, we see an immediate conflict with respect to the duty of the physician/genetic counselor to maintain confidentiality in concert with the duty to warn.
A subcommittee of the American Society of Human Genetics dealing with family disclosure, 51 has suggested that ethical, legal, and statutory exceptions, 'ylimit the principle of confidentiality and, in specific and very limited circumstances, may permit disclosure. At the very least, it is clear that a healthcare professional has a positive duty to inform a patient about potential genetic risks to the patient's relativesy' Where certain preventive action can be taken, the duty to warn becomes of compelling concern.
MSI/IHC and recognition of Lynch syndrome: standards of care upgraded?
It is our premise that when a patient presents with CRC, the endoscopist, surgeon, and oncologist have the responsibility to recognize the possibility that an hereditary predisposition may be present. Most cases will sort themselves out as clearly hereditary (diffuse polyposis at an early age) or clearly sporadic (an elderly patient with no family history of malignancy). In between lies the challenging world of possible Lynch syndrome. In this syndrome, early age of onset has been ingrained in the literature, although Hampel et al, 52 as mentioned, have called appropriate attention to older onset (55 -60 years). The presence of major clues such as fulfillment of the Amsterdam criteria, very early age at onset, multiple primary cancers that are integral to Lynch syndrome, and/or the presence of key pathologic features, collectively may provide a basis for MMR gene testing. However, because the sensitivity of mutational testing is low when predicated on these features, any measure that can be employed to increase the specificity of mutational testing without compromising sensitivity should be considered. The predictive power of MSI and/or IHC for loss of MMR gene expression must be considered and have been found to be increasingly helpful in this regard. 27 Several large series have now shown that the yield of mutational testing is low when a tumor is microsatellite stable, even when the family history is otherwise very suggestive. Conversely, with the exception of methylation-mediated silencing of MLH1, which can lead to a 'false positive' tumor screen, MSI and IHC serve as reliable predictors of an underlying Lynch syndrome mutation, even when the family history is soft or the patient is older. For these reasons, our threshold for conducting MSI/IHC has become rather low. 10 
Amsterdam criteria positive but MMR-negative cohort
Lindor et al 53 described 3422 relatives from 161 Amsterdam criteria I (AC-1) families and divided them via tumor testing into group A (with MMR deficiency) and group B (without MMR deficiency. Group A families showed an increased incidence of Lynch syndrome-related cancers while group B families showed an increase only for CRC, and even then to a lesser extent than group A. It was concluded that families who fulfill AC-1 criteria but lack evidence of DNA MMR defect do not show the same cancer incidence as families with Lynch syndrome and an MMR deficiency. Furthermore, those relatives in group B families also showed a lower incidence of those extracolonic cancers integral to Lynch syndrome when compared with their group A counterparts. These authors suggest that families in the group B category 'yshould not be described or counseled as having HNPCC -Lynch syndrome.' To facilitate distinguishing these entities, the designation of 'familial CRC type X' was suggested to describe this type of familial aggregation of CRC. 53 However, to avoid confusion with X chromosomal inheritance we prefer the designation 'familial CRC of undetermined type.' We advocate surveillance of these high-risk patients comparable to that for the Lynch syndrome. It is also pertinent to note that Lynch et al 54 The sine qua non, the identification of a germline MMR mutation segregating with syndrome-affected individuals in the family.
Cancer control in Lynch syndrome
Cancer-related morbidity and mortality may be reduced significantly through highly targeted surveillance and management measures that are based on knowledge of the natural history and cardinal features of the Lynch syndrome. Particularly important is full colonoscopy (due to the syndrome's predilection toward proximal CRC), 62 initiated at the age of 25 years (due to early onset of CRC), 3 with good cleanout for visualization to the cecum, and repeated annually (due to accelerated carcinogenesis). 4, 63 For women, endometrial aspiration coupled with transvaginal ultrasound is advised for screening, beginning at the age of 30 -35 years. We recommend semiannual CA 125 testing, beginning at the same age, for ovarian cancer. Women must be advised of the marked limitations in ovarian cancer screening. 64 Prophylactic hysterectomy and oophorectomy can then be considered when childbearing is completed. These cancer control strategies impact heavily upon at-risk family members once they have been counseled and educated thoroughly about Lynch syndrome's natural history and their own hereditary cancer risk. Figure 3 is an algorithm showing proposed steps in the diagnosis and management of Lynch syndrome patients.
Does colonoscopy work?
Järvinen et al 65 demonstrated the lifesaving benefit of colonoscopic surveillance in Lynch syndrome through a controlled clinical trial extending over 15 years. The incidence of CRC was compared in two cohorts (screened and nonscreened) of at-risk members of 22 Lynch syndrome families. The nonscreened (controls) were family members who were noncompliant with respect to colonoscopy. CRC developed in eight screened subjects (6%), compared with 19 unscreened controls (16%; P ¼ 0.014). The CRC rate was reduced by 62% in those who were screened. All CRCs in the screened group were local, causing no deaths, compared with nine deaths caused by CRC in the controls. It was concluded that CRC surveillance at 3-year intervals more than cuts in half the CRC risk, prevents CRC deaths, and decreases overall mortality by about 65% in Lynch syndrome families. The relatively high incidence of CRC even in the screened subjects (albeit without deaths) argues for shorter intervals between colonoscopies, for example, 1 year. 
Chemotherapy concerns
The absence of a positive response to 5-fluorouracil (5-FU) in Lynch syndrome In 1993, Parsons et al 69 reported that the colon cancer cell line HCT116 had MSI, and an extract from these cells failed to repair mismatched DNA heteroduplexes. It was later shown that the MLH1 gene on chromosome 3p was homozygously mutated in these cells. In 1994, Koi et al 70 derived a cell line from HCT116 by stably transferring another copy of chromosome 3 into the parental line. The cell line, HCT116 þ ch3, expressed MLH1 mRNA and protein, had a restoration of DNA MMR activity, and the microsatellite stability was corrected. Importantly, restoration of the DNA MMR activity reduced the tolerance of the tumor cells to the toxic alkylating agent, MNNG. The group subsequently demonstrated that correction of the DNA MMR system also restored the G2/M cell cycle checkpoint to the tumor cells. Thus, critical degrees of DNA damage, induced either by MNNG or 6-thioguanine, would induce G2/M cell cycle arrest in the DNA MMRproficient cell line, whereas the parental HCT116 cell line tolerated this challenge, and presumably, would be susceptible to the accumulation of an additional mutational load if challenged. 71 Carethers et al 72 then found that competency of the DNA MMR system prohibited clonal expansion of cancer cells after exposure to MNNG, using a panel of cell lines that were DNA MMR proficient (such as SW480 or HCT116 þ ch3). Contrariwise, the cloning efficiency after DNA damage was significantly higher in the DNA MMR-deficient cell lines HCT116, the chromosome 2 transferred line HCT116 þ ch2 (which served as a control for chromosome 3 transfer), the cell line HCT116 þ ch3M2 (in which the MLH1 gene had been inactivated by mutation from HCT116 þ ch3 cells), as well as cell lines LoVo and 2774. The observation that an abnormality in DNA MMR conferred resistance to DNA damage had been made by Branch et al 73 -75 in non-colonic cells even before the human DNA MMR genes had been identified or linked to Lynch syndrome. These observations established that the DNA MMR system participated in the cell death response to DNA damage, which is the principal mechanism by which cancer chemotherapy kills cancer cells. In order to determine whether a similar response would be found using 5-FU, colony forming activity in the presence of this drug was examined in MMR-deficient and MMR-proficient cell lines. All of the cell lines with defective DNA MMR activity, whether due to defective MLH1 activity (HCT116) or defective MSH2 activity (LoVo, 2774), were more tolerant of doses of 5-FU up to 5 mM. Contrariwise, the DNA MMR-corrected cell line HCT116 þ ch3, and the CRC cell line SW480, which is DNA MMR proficient, showed a dose-related fall in colony-forming activity after exposure to 5-FU. Importantly, this dose of 5-FU is pharmacologically relevant, and suggested that clinical resistance to 5 Because these patients were under 50 years of age, most were thought to have Lynch syndrome. In fact, it was the failure to take the MSI factor into account properly that led to the spurious report that a survival benefit had been achieved in a retrospective study of adjuvant chemotherapy in patients with MSI þ CRCs. 76 Precisely the opposite was actually true. The fatal flaw of this study was the use of a retrospective study design, and the failure to randomize the patients prior to selection for chemotherapy. Because patients with Lynch syndrome tend to be substantially younger and apparently healthier than those with sporadic colon cancer, there is a tendency to preferentially select these patients for adjuvant chemotherapy. Subsequently, it was demonstrated in a large, prospective, randomized study of chemotherapy that 5-FU was of benefit to patients with CRCs that were microsatellite stable, but a modest, two-fold hazard ratio for death was found among those patients who received 5-FU if their tumor was MSI þ . 44 caused by the epigenetic silencing of MLH1 and other tumor suppressor genes), these groups may need to be considered separately. 48 
Discussion and summary
Can generalizations be drawn regarding the approach to the next clinic patient who enters your clinic? The answer is a qualified yes, so let us begin. The history and physical may provide clues. Family history may point to the presence of Amsterdam criteria. For better or worse, even when the patient is familiar with details of his or her family history, most cases eventually found to be Lynch syndrome do not have family histories that meet these rather rigorous, narrow criteria. More likely in the clinic setting, the clinician is confronted with a single patient whose personal history of early-onset CRC has prompted a more detailed risk assessment. In the complete absence of family history (eg, in case of adoption with closed adoption records), the early onset alone may well be enough to trigger MSI/IHC testing. Otherwise, virtually any additional family history of Lynch syndrome-associated tumors will be enough to prompt MSI/IHC. Occasionally, the history of an earlier personal diagnosis of colorectal or endometrial cancer will raise the question, even if the patient is now older. In other cases, sebaceous tumors may point to the Muir-Torre variant. In still others, the pathology of the resected tumor may raise a suspicion for Lynch syndrome. Perhaps an endoscopic biopsy will have presented an opportunity for MSI/IHC which can be carried out prior to surgical resection and which may support a more aggressive scope of resection (subtotal colectomy as opposed to segmental resection), even if definitive mutational testing cannot be carried out during the window of time between endoscopic diagnosis and surgery. As the recent data from large series of CRCs from Finland, 77 the Mayo Clinic, 37 and Ohio 10 demonstrate, no one clinical, family history, or pathologic consideration carries with it sufficient sensitivity and specificity for Lynch syndrome as to constitute a sole basis for selection for further testing. For better or worse, informed clinical judgment as to likely yield, coupled with the patient's own threshold for willingness to undergo further evaluation, will determine whether or not MSI/IHC is performed. This approach, which is practiced universally, inevitably leads to severe underdiagnosis of Lynch syndrome. A better approach is to practice some form of molecular screening on all newly diagnosed CRC patients. The feasibility of this approach is being explored. 10 Further studies, including the use of IHC as the primary screen, and incorporating cost -benefit analyses, will be necessary before general recommendations can be proffered. If the decision is made to proceed with MSI/IHC and appropriate counseling has been provided, most patients will choose to follow up an informative result with mutational testing. The choice not to pursue mutational testing despite informative MSI/IHC likely reflects poor communications during the initial clinical/genetic counseling experience. The more difficult decision is whether to do further testing if MSI/IHC is not informative. Here, the weight of pretest clinical risk and patient determination make for challenging decision making. When mutational testing is pursued, whether following an informative MSI/ IHC, following an uninformative MSI/IHC, or without the use of MSI/IHC at all (as is the practice of some), even more difficult challenges in interpretation exist. The easy case is a test that is positive for a pathologic MMR gene mutation. Again, if communications have been effective to this point, most subjects will have already decided to inform at-risk relatives of the findings, perhaps aided by educational materials that have been offered by those doing the counseling and/or testing. What to do when the mutational test yields no mutation can be complicated. If, for example, there was loss of MSH2-associated protein, the germline mutation test may well have been a false negative, representing limitations in the testing itself. If additional testing is possible (rearrangement studies, diploid -haploid conversion-aided testing, segregation analysis), then they may be considered. If no prior MSI/ IHC was carried out, one might wish to 'back-track' and do so. If for any reason the mutational testing was considered low yield in the first place (eg, carried out despite uninformative MSI/IHC), one may simply choose to offer empiric surveillance recommendations, that is, to do surveillance in 'at-risk' relatives 'as if' they were carriers. An unfortunately common situation involves mutational testing that yields a variant 'of uncertain significance. ' It is important that colon cancer surveillance be cast in the perspective of general population vs hereditary CRC. Central to these concerns is the fact that hereditary CRC surveillance differs strikingly from general population CRC surveillance guidelines. 78 As recently as 1990, there was a marked paucity of guidelines for hereditary CRC surveillance, and no widely endorsed guidelines for general-population CRC surveillance. There was even disagreement among trusted organizations about which tests were recommended or even whether any tests for screening would be appropriate for the general population. Ransohoff 78 notes that when screening was performed at all, fecal occult blood testing (FOBT) was the most common test, with sigmoidoscopy less frequently used. Colonoscopy was rarely used for surveillance. The question of whether CRC screening of any kind would reduce CRC mortality was still unanswered. 
